277 related articles for article (PubMed ID: 27556700)
1. Identification of breast cancer cell subtypes sensitive to ATG4B inhibition.
Bortnik S; Choutka C; Horlings HM; Leung S; Baker JH; Lebovitz C; Dragowska WH; Go NE; Bally MB; Minchinton AI; Gelmon KA; Gorski SM
Oncotarget; 2016 Oct; 7(41):66970-66988. PubMed ID: 27556700
[TBL] [Abstract][Full Text] [Related]
2. A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells.
Papadakis E; Robson N; Yeomans A; Bailey S; Laversin S; Beers S; Sayan AE; Ashton-Key M; Schwaiger S; Stuppner H; Troppmair J; Packham G; Cutress R
Oncotarget; 2016 Apr; 7(14):18851-64. PubMed ID: 26958811
[TBL] [Abstract][Full Text] [Related]
3. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
4. SLC27A4 regulate ATG4B activity and control reactions to chemotherapeutics-induced autophagy in human lung cancer cells.
Wu S; Su J; Qian H; Guo T
Tumour Biol; 2016 May; 37(5):6943-52. PubMed ID: 26662804
[TBL] [Abstract][Full Text] [Related]
5. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
6. HSF1 upregulates ATG4B expression and enhances epirubicin-induced protective autophagy in hepatocellular carcinoma cells.
Zhang N; Wu Y; Lyu X; Li B; Yan X; Xiong H; Li X; Huang G; Zeng Y; Zhang Y; Lian J; Ni Z; He F
Cancer Lett; 2017 Nov; 409():81-90. PubMed ID: 28889000
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
Xu W; Bi Y; Zhang J; Kong J; Jiang H; Tian M; Li K; Wang B; Chen C; Song F; Pan X; Shi B; Kong X; Gu J; Cai X; Li Z
Oncotarget; 2015 Nov; 6(36):38840-53. PubMed ID: 26474285
[TBL] [Abstract][Full Text] [Related]
8. Context-dependent role of ATG4B as target for autophagy inhibition in prostate cancer therapy.
Tran E; Chow A; Goda T; Wong A; Blakely K; Rocha M; Taeb S; Hoang VC; Liu SK; Emmenegger U
Biochem Biophys Res Commun; 2013 Nov; 441(4):726-31. PubMed ID: 24184480
[TBL] [Abstract][Full Text] [Related]
9. Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib.
Chen S; Zhu X; Qiao H; Ye M; Lai X; Yu S; Ding L; Wen A; Zhang J
Tumour Biol; 2016 Feb; 37(2):2321-31. PubMed ID: 26369543
[TBL] [Abstract][Full Text] [Related]
10. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
Gardaneh M; Shojaei S; Kaviani A; Behnam B
Breast Cancer Res Treat; 2017 Apr; 162(2):231-241. PubMed ID: 28116540
[TBL] [Abstract][Full Text] [Related]
11. Autophagy related 4B, upregulated by HIF-1α, attenuates the sensitivity to cisplatin in nasopharyngeal carcinoma cells.
Huang J; Li HB; Yu S; Yuan F; Lou ZP
Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4793-4802. PubMed ID: 32432742
[TBL] [Abstract][Full Text] [Related]
12. ATG4B inhibitors with a benzotropolone core structure block autophagy and augment efficiency of chemotherapy in mice.
Kurdi A; Cleenewerck M; Vangestel C; Lyssens S; Declercq W; Timmermans JP; Stroobants S; Augustyns K; De Meyer GRY; Van Der Veken P; Martinet W
Biochem Pharmacol; 2017 Aug; 138():150-162. PubMed ID: 28642033
[TBL] [Abstract][Full Text] [Related]
13. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
14. Identification of lysosome-targeting drugs with anti-inflammatory activity as potential invasion inhibitors of treatment resistant HER2 positive cancers.
Hansen MB; Postol M; Tvingsholm S; Nielsen IØ; Dietrich TN; Puustinen P; Maeda K; Dinant C; Strauss R; Egan D; Jäättelä M; Kallunki T
Cell Oncol (Dordr); 2021 Aug; 44(4):805-820. PubMed ID: 33939112
[TBL] [Abstract][Full Text] [Related]
15. β2-AR signaling controls trastuzumab resistance-dependent pathway.
Liu D; Yang Z; Wang T; Yang Z; Chen H; Hu Y; Hu C; Guo L; Deng Q; Liu Y; Yu M; Shi M; Du N; Guo N
Oncogene; 2016 Jan; 35(1):47-58. PubMed ID: 25798840
[TBL] [Abstract][Full Text] [Related]
16. An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts.
Chen Q; Weng Z; Lu Y; Jia Y; Ding L; Bai F; Ge M; Lin Q; Wu K
PLoS One; 2017; 12(1):e0168960. PubMed ID: 28045951
[TBL] [Abstract][Full Text] [Related]
17. Autophagy related markers (Beclin-1 and ATG4B) are strongly expressed in Wilms' tumor and correlate with favorable histology.
Guimei M; Eladl MA; Ranade AV; Manzoor S
Histol Histopathol; 2019 Jan; 34(1):47-56. PubMed ID: 29989143
[TBL] [Abstract][Full Text] [Related]
18. A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors.
Akin D; Wang SK; Habibzadegah-Tari P; Law B; Ostrov D; Li M; Yin XM; Kim JS; Horenstein N; Dunn WA
Autophagy; 2014; 10(11):2021-35. PubMed ID: 25483883
[TBL] [Abstract][Full Text] [Related]
19. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.
Chittaranjan S; Bortnik S; Dragowska WH; Xu J; Abeysundara N; Leung A; Go NE; DeVorkin L; Weppler SA; Gelmon K; Yapp DT; Bally MB; Gorski SM
Clin Cancer Res; 2014 Jun; 20(12):3159-73. PubMed ID: 24721646
[TBL] [Abstract][Full Text] [Related]
20. Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids.
Rodríguez CE; Reidel SI; Bal de Kier Joffé ED; Jasnis MA; Fiszman GL
PLoS One; 2015; 10(9):e0137920. PubMed ID: 26360292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
